If AT can buy into a manufacturing facility, and strike a funding deal also, this would be very positive for the company. We already know how good the clinical data is and will continue to be, so cementing manufacturing and supply chain would be incredible. Then we need breakthrough designation from the FDA, and Clarity will be off to the races and on the way to build an Australian biotech power house. This is ofcourse if BP cannot stump up the dollars.
CU6 Price at posting:
$1.75 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)